aTyr Pharma (NASDAQ:ATYR) Upgraded by Wall Street Zen to “Hold” Rating

aTyr Pharma (NASDAQ:ATYR) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Sunday.

Other equities analysts have also issued reports about the company. Weiss Ratings lowered aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, June 26th. Freedom Capital upgraded shares of aTyr Pharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $17.00.

aTyr Pharma Stock Down 6.4%

Shares of ATYR stock traded down $0.04 on Friday, reaching $0.54. 1,368,176 shares of the stock were exchanged, compared to its average volume of 2,137,444. The stock has a market cap of $53.38 million, a P/E ratio of -0.75 and a beta of 0.52. The firm has a 50 day moving average of $0.56 and a two-hundred day moving average of $0.74. aTyr Pharma has a 1-year low of $0.40 and a 1-year high of $7.29.

aTyr Pharma (NASDAQ:ATYR) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. On average, equities research analysts predict that aTyr Pharma will post -0.66 EPS for the current fiscal year.

Insider Activity

In other news, Director Paul Schimmel bought 100,000 shares of aTyr Pharma stock in a transaction dated Wednesday, May 27th. The shares were acquired at an average cost of $0.50 per share, with a total value of $50,000.00. Following the completion of the transaction, the director owned 779,143 shares in the company, valued at approximately $389,571.50. This trade represents a 14.72% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.75% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On aTyr Pharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System purchased a new position in aTyr Pharma in the 2nd quarter valued at about $28,000. Renaissance Technologies LLC purchased a new stake in shares of aTyr Pharma during the first quarter worth about $32,000. ADAR1 Capital Management LLC lifted its stake in shares of aTyr Pharma by 35.9% in the fourth quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock worth $40,000 after acquiring an additional 13,385 shares in the last quarter. Kingswood Wealth Advisors LLC acquired a new position in shares of aTyr Pharma in the fourth quarter worth about $41,000. Finally, Legal & General Group Plc purchased a new position in aTyr Pharma in the second quarter valued at about $49,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.